Theranos and Trump both sold radical openness as proof of integrity

The Atlantic piece links Holmes’s staged lab tours and Trump’s selective document releases to Nathan Fielder’s staged-reality experiments, yet stops short of naming the shared incentive structure. Both figures operated inside environments where demonstrable openness functions as a substitute for audited outcomes: venture funding for Theranos and media attention for Trump rewarded visible gestures over verifiable results. Holmes’s public claims of FDA-level transparency coincided with withheld machine data; Trump’s “most transparent administration” rhetoric aligned with delayed or redacted financial disclosures. The pattern persists because the institutions that distribute capital and coverage still treat performative access as evidence of accountability rather than a low-cost signal. Platform algorithms and investor decks continue to amplify the same loop: visible candor clips generate engagement while underlying metrics remain gated. This produces a durable market for figures who can stage transparency without surrendering control. Expect the same template to appear in AI governance statements that publish model cards yet withhold training data provenance.